Skip to main content

PIK3CA

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Geoffrey Ku, MD
Videos
09/08/2026
Geoffrey Ku, MD
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses findings from the phase 3 HERIZON-GEA-01 trial evaluating first-line zanidatamab plus chemotherapy, with or without tislelizumab, in patients with HER2-positive gastroesophageal adenocarcinoma, highlighting improved...
Geoffrey Ku, MD, discusses...
09/08/2026
Oncology
Viktor Grünwald, MD, PhD
Videos
09/02/2026
Viktor Grünwald, MD, PhD
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD, discusses results from the phase 2 OPTIM study evaluating nivolumab plus ipilimumab versus docetaxel after failure to respond to nivolumab in head and neck cancer, highlighting the need for novel strategies to...
Viktor Grünwald, MD, PhD,...
09/02/2026
Oncology
Allen Khudaverdyan, MD
Videos
09/02/2026
Allen Khudaverdyan, MD
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD, discusses results from a large retrospective study evaluating concurrent statin use in patients with head and neck squamous cell carcinoma receiving immune checkpoint inhibitors, highlighting statin-specific survival...
Allen Khudaverdyan, MD,...
09/02/2026
Oncology
Christopher Noel, MD, PhD
Videos
09/02/2026
Christopher Noel, MD, PhD
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD, discusses a cost-effectiveness analysis of perioperative pembrolizumab in locally advanced head and neck cancer, highlighting how current drug pricing and treatment duration may limit cost-effectiveness despite the...
Christopher Noel, MD, PhD,...
09/02/2026
Oncology
Andrew Hahn, MD
Videos
08/27/2026
Andrew Hahn, MD
Andrew Hahn, MD, discusses a case of de novo metastatic prostate cancer, highlighting how comprehensive molecular profiling can guide treatment intensification with androgen-deprivation therapy, an androgen receptor pathway inhibitor, and...
Andrew Hahn, MD, discusses a case of de novo metastatic prostate cancer, highlighting how comprehensive molecular profiling can guide treatment intensification with androgen-deprivation therapy, an androgen receptor pathway inhibitor, and...
Andrew Hahn, MD, discusses a...
08/27/2026
Oncology
Diwakar Davar, MBBS
Videos
08/18/2026
Diwakar Davar, MBBS
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses results from the phase 1/2 IMA203-101 trial evaluating the PRAME-directed T-cell receptor therapy anzu-cel in patients with advanced melanoma, highlighting durable responses, a manageable safety profile, and the...
Diwakar Davar, MBBS, discusses...
08/18/2026
Oncology
Shubham Pant, MD
Videos
08/17/2026
Shubham Pant, MD
Shubham Pant, MD, explores how emerging RAS-targeted therapies may offer new treatment opportunities for patients with KRAS G12D–mutated metastatic pancreatic cancer.
Shubham Pant, MD, explores how emerging RAS-targeted therapies may offer new treatment opportunities for patients with KRAS G12D–mutated metastatic pancreatic cancer.
Shubham Pant, MD, explores how...
08/17/2026
Oncology
Craig L. Slingluff, Jr., MD
Videos
08/12/2026
Craig Slingluff, MD
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses...
08/12/2026
Oncology
Sikander Ailawadhi, MD
Videos
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology
Barbara Burtness, MD
Videos
08/06/2026
Barbara Burtness, MD, FASCO
Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...
Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...
Barbara Burtness, MD, discusses...
08/06/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
FDA Approval
09/09/2026
Stephanie Holland
The FDA expanded the accelerated approval of sevabertinib to adults with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 activating mutations, extending the targeted therapy into the first-line setting...
The FDA expanded the accelerated approval of sevabertinib to adults with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 activating mutations, extending the targeted therapy into the first-line setting...
The FDA expanded the accelerated...
09/09/2026
Oncology
FDA Approval
09/08/2026
Emily Estrada
Based on results from the phase 3 SERENA-6 trial, the FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer following detection of an ESR1 mutation during ongoing...
Based on results from the phase 3 SERENA-6 trial, the FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer following detection of an ESR1 mutation during ongoing...
Based on results from the phase...
09/08/2026
Oncology
News
09/03/2026
Stephanie Holland
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that...
09/03/2026
Oncology
News
09/03/2026
Stephanie Holland
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3...
09/03/2026
Oncology
News
09/02/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi...
09/02/2026
Oncology
News
09/02/2026
Stephanie Holland
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3...
09/02/2026
Oncology
News
09/01/2026
Stephanie Holland
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase...
09/01/2026
Oncology
News
08/31/2026
Emily Estrada
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase...
08/31/2026
Oncology
News
08/31/2026
Stephanie Holland
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01...
08/31/2026
Oncology
News
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology